Gaudium IVF Launches New South Delhi Centre Featuring AI-Powered Signature Labs
Gaudium IVF and Women Health Limited, India's first publicly listed fertility chain, has launched a new centre in South Delhi. This facility marks the initial milestone in the company's planned 19-centre expansion roadmap. The launch is designed to provide standardized, technology-driven fertility care through a model that combines AI innovation with clinical excellence and patient safety.The new centre features the Gaudium Signature Lab, which is the company's proprietary laboratory framework. This system integrates advanced embryology and AI-powered technologies to create an optimal environment for embryo development. As the company expands its network, the Signature Lab model will be replicated across every new centre to ensure patients experience consistent standards of precision and safety regardless of location.
The facility incorporates Gaudium IVF's AI-powered embryology ecosystem, which includes specific tools for advanced reproductive medicine:
| Technology | Application |
|---|---|
| SiD (Sperm Identification Device) | Advanced sperm assessment |
| ERICA (Embryo Ranking Intelligent Classification Assistant) | Embryo evaluation |
| Signature Lab Model | Integrated proprietary framework for embryo development |
The company has a 17-year legacy in fertility care, having been founded in 2009. Its commitment to laboratory excellence has received international recognition through the European Quality Award from ESQR, Spain. This recognition reinforces the high standards used by the company in treating complex infertility and recurrent IVF failure cases.
Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF, stated that the launch of the South Extension centre reflects a commitment to making world-class fertility care more accessible without compromising on the standards established over the past 17 years. She noted that the focus remains on building centres that combine scientific excellence, AI-powered innovation, and globally benchmarked laboratory standards with a patient-first approach.
The expansion comes as demand for specialized fertility care grows in India due to delayed parenthood, changing lifestyles, and increased awareness of assisted reproductive technologies. Through its planned network, Gaudium IVF aims to replicate the Signature Lab model across new centres to deliver high-quality fertility care at scale while maintaining a leadership position in the evolving fertility care sector.
GAUDIUMIVF Stock Price Movement
Gaudium IVF and Women Health Limited shares are slipping by 0.92% to ₹129.63 as of 2:17 PM in live trading. The stock is experiencing a total traded volume of 119,974 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.